BMS Prepares To Move Opdivo Into Neoadjuvant Lung Cancer

Bristol Myers Squibb Company appears ready to file for approval of an early-stage non-small cell lung cancer indication with Opdivo, a potentially important milestone as it battles with Merck & Co., Inc. for earlier-stage cancer settings for their checkpoint inhibitors. But as the first neoadjuvant treatment for NSCLC, it will have to prepare the market.

On 8 November, the pharma reported that its anti-PD-1 Opdivo plus chemotherapy bested chemo alone on event-free survival (EFS) as neoadjuvant treatment of early-stage, resectable NSCLC.